Yahoo Finance Top 3 UK Stocks Estimated To Be Undervalued In July 2024
The United Kingdom's stock market has recently experienced declines, influenced by disappointing trade data from China and its broader economic challenges. Amidst these market conditions, identifying undervalued stocks can offer investors potential opportunities for value in a landscape marked by global uncertainties. In this environment, a good stock may be characterized by robust fundamentals such as strong balance sheets and consistent earnings, which provide resilience against ongoing market volatilities.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
Name | Current Price | Fair Value (Est) | Discount (Est) |
Begbies Traynor Group (AIM:BEG) | £1.01 | £1.98 | 48.9% |
Gaming Realms (AIM:GMR) | £0.3655 | £0.69 | 46.9% |
WPP (LSE:WPP) | £7.414 | £14.28 | 48.1% |
Calnex Solutions (AIM:CLX) | £0.49 | £0.98 | 49.8% |
LSL Property Services (LSE:LSL) | £3.35 | £6.33 | 47.1% |
Ibstock (LSE:IBST) | £1.82 | £3.41 | 46.5% |
Auction Technology Group (LSE:ATG) | £4.855 | £9.69 | 49.9% |
Accsys Technologies (AIM:AXS) | £0.552 | £1.06 | 47.8% |
Entain (LSE:ENT) | £6.452 | £12.34 | 47.7% |
Nexxen International (AIM:NEXN) | £2.475 | £4.82 | 48.6% |
Underneath we present a selection of stocks filtered out by our screen.
LBG Media
Overview: LBG Media plc is an online media publisher operating in the United Kingdom, Ireland, Australia, the United States, and internationally, with a market capitalization of approximately £247.76 million.
Operations: The company generates £67.51 million in revenue from its online media publishing operations.
Estimated Discount To Fair Value: 20.5%
LBG Media, priced at £1.19, is currently valued below its estimated fair value of £1.49, indicating a potential undervaluation by over 20%. Despite this, the company shows promising growth prospects with earnings expected to increase by 43.84% annually. However, it's important to note that LBG's return on equity is anticipated to be modest at 16.1% in three years' time and recent financial results have been affected by significant one-off items. Revenue growth projections also outpace the UK market average significantly at 11.7% per year.
AstraZeneca
Overview: AstraZeneca PLC is a biopharmaceutical company engaged in the discovery, development, manufacture, and commercialization of prescription medicines, with a market capitalization of approximately £189.35 billion.
Operations: The company generates its revenue primarily from the biopharmaceuticals segment, which amounted to $47.61 billion.
Estimated Discount To Fair Value: 42%
AstraZeneca, a prominent pharmaceutical firm, showcased robust financial performance in its recent earnings report. For Q2 2024, the company reported significant year-over-year increases in sales to US$482 million and net income to US$1.927 billion. This growth is supported by strategic product launches and regulatory approvals, such as Voydeya for PNH treatment in Canada, enhancing its revenue streams from high-margin products. Despite these strengths, investors should consider the inherent risks of drug development and market competition that could impact future cash flows.
The growth report we've compiled suggests that AstraZeneca's future prospects could be on the up.
Take a closer look at AstraZeneca's balance sheet health here in our report.
Informa
Overview: Informa plc is a global company based in the UK, specializing in international events, digital services, and academic research, with a market capitalization of approximately £11.60 billion.
Operations: The company's revenue is divided into four key segments: Informa Tech generates £426.70 million, Informa Connect brings in £630.20 million, Informa Markets contributes £1.67 billion, and Taylor & Francis accounts for £636.70 million in revenues.
Estimated Discount To Fair Value: 42.3%
Informa is currently trading at £8.78, significantly below its estimated fair value of £15.23, indicating a potential undervaluation based on discounted cash flow analysis. Despite this, the company's recent half-year earnings report showed a decline in net income to £147.3 million from £253.5 million year-over-year, with basic earnings per share also decreasing. However, Informa's revenue is expected to grow faster than the UK market average, with forecasts predicting significant earnings growth over the next three years and an unstable dividend track record that may concern some investors.
Next Steps
Click here to access our complete index of 61 Undervalued UK Stocks Based On Cash Flows.
Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:LBG LSE:AZN and LSE:INF.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
